XML 40 R25.htm IDEA: XBRL DOCUMENT

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Mar. 31, 2025 shares
Trading Arrangements, by Individual
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Robert F. Probst [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On February 19, 2025, Robert F. Probst, Executive Vice President and Chief Financial Officer of the Company, adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Probst’s trading plan covers (i) the sale of an amount of shares of our common stock necessary to generate an aggregate of up to $4.6 million in net proceeds and (ii) the potential exercise and sale of up to 320,057 shares of our common stock with respect to expiring options, in each case in amounts and prices determined in accordance with a formula set forth in the plan, and terminates on the earlier of the date all the shares under the plan are sold and January 15, 2027.
Name	Robert F. Probst
Title	Executive Vice President and Chief Financial Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	February 19, 2025
Expiration Date	January 15, 2027
Arrangement Duration	695 days
Aggregate Available	320,057
Peter J. Bulgarelli [Member]
Trading Arrangements, by Individual
Material Terms of Trading Arrangement	On February 20, 2025, Peter J. Bulgarelli, Executive Vice President, Outpatient Medical and Research of the Company and President and CEO of Lillibridge Healthcare Services, Inc., adopted a trading plan intended to satisfy the conditions under Rule 10b5-1(c) of the Exchange Act. Mr. Bulgarelli’s trading plan is for the sale of up to 15,000 shares of our common stock in amounts and prices determined in accordance with a formula set forth in the plan and terminates on the earlier of the date all the shares under the plan are sold and February 20, 2026.
Name	Peter J. Bulgarelli
Title	Executive Vice President, Outpatient Medical and Research
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	February 20, 2025
Expiration Date	February 20, 2026
Arrangement Duration	365 days
Aggregate Available	15,000